CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 338,700 shares, an increase of 88.1% from the March 15th total of 180,100 shares. Currently, 11.6% of the company’s stock are short sold. Based on an average daily trading volume, of 634,900 shares, the short-interest ratio is currently 0.5 days.

Institutional Investors Weigh In On CNS Pharmaceuticals

A number of institutional investors have recently made changes to their positions in CNSP. Citadel Advisors LLC bought a new position in CNS Pharmaceuticals during the 4th quarter worth $39,000. Jane Street Group LLC lifted its position in CNS Pharmaceuticals by 1,712.3% during the fourth quarter. Jane Street Group LLC now owns 419,737 shares of the company’s stock worth $51,000 after purchasing an additional 396,577 shares during the period. Connective Capital Management LLC bought a new stake in CNS Pharmaceuticals during the fourth quarter worth about $34,000. Integrated Wealth Concepts LLC acquired a new stake in CNS Pharmaceuticals during the fourth quarter worth about $30,000. Finally, Geode Capital Management LLC increased its holdings in CNS Pharmaceuticals by 90.5% in the 4th quarter. Geode Capital Management LLC now owns 387,064 shares of the company’s stock valued at $47,000 after buying an additional 183,884 shares during the period. Institutional investors own 14.02% of the company’s stock.

CNS Pharmaceuticals Price Performance

CNSP stock traded down $0.00 during midday trading on Thursday, reaching $0.82. 172,516 shares of the company were exchanged, compared to its average volume of 288,127. The firm has a market capitalization of $2.41 million, a price-to-earnings ratio of -0.01 and a beta of 2.72. The business has a 50-day moving average price of $2.72 and a two-hundred day moving average price of $4.70. CNS Pharmaceuticals has a one year low of $0.77 and a one year high of $800.00.

Wall Street Analysts Forecast Growth

CNSP has been the subject of a number of recent analyst reports. Maxim Group reiterated a “hold” rating on shares of CNS Pharmaceuticals in a research note on Tuesday, March 25th. Alliance Global Partners raised CNS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 24th.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.